Can-Fite BioPharma Ltd. (CANF)
USD 1.33
(-6.34%)
USD 1.33
(-6.34%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.79 USD | 52.0% |
| 2022 | -0.01 USD | 54.55% |
| 2021 | -0.03 USD | 34.99% |
| 2020 | -0.04 USD | 71.8% |
| 2019 | -0.15 USD | 11.76% |
| 2018 | -0.17 USD | 10.53% |
| 2017 | -0.19 USD | 36.67% |
| 2016 | -0.30 USD | -11.11% |
| 2015 | -0.27 USD | 22.86% |
| 2014 | -0.35 USD | 42.62% |
| 2013 | -0.61 USD | -8.93% |
| 2012 | -0.56 USD | 99.74% |
| 2011 | -214.89 USD | -69.2% |
| 2010 | -127.00 USD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.00 USD | 0.0% |
| 2024 Q1 | -0.00 USD | 0.0% |
| 2023 Q4 | -0.00 USD | 21.43% |
| 2023 Q2 | -0.00 USD | 36.36% |
| 2023 FY | - USD | 52.39% |
| 2023 Q1 | -0.00 USD | 40.54% |
| 2023 Q3 | -0.00 USD | 0.0% |
| 2022 Q4 | -0.00 USD | -19.35% |
| 2022 Q1 | -0.00 USD | 70.3% |
| 2022 Q2 | -0.00 USD | 10.0% |
| 2022 Q3 | -0.00 USD | -14.81% |
| 2022 FY | - USD | 44.95% |
| 2021 Q4 | -0.01 USD | -62.9% |
| 2021 FY | - USD | 44.87% |
| 2021 Q1 | -0.00 USD | 50.0% |
| 2021 Q2 | -0.01 USD | -58.97% |
| 2021 Q3 | -0.01 USD | 0.0% |
| 2020 Q3 | -0.01 USD | 55.56% |
| 2020 Q4 | -0.01 USD | -39.29% |
| 2020 Q1 | -0.03 USD | 31.98% |
| 2020 FY | - USD | 72.82% |
| 2020 Q2 | -0.01 USD | 49.8% |
| 2019 Q1 | -0.04 USD | 52.89% |
| 2019 FY | - USD | -26711.76% |
| 2019 Q4 | -0.04 USD | -14.6% |
| 2019 Q2 | -0.04 USD | -5.0% |
| 2019 Q3 | -0.03 USD | 23.33% |
| 2018 Q4 | -0.08 USD | -1874.42% |
| 2018 FY | - USD | -13.33% |
| 2018 Q2 | -0.03 USD | 37.4% |
| 2018 Q3 | -0.00 USD | 86.26% |
| 2018 Q1 | -0.05 USD | 32.89% |
| 2017 Q2 | -0.06 USD | -34.54% |
| 2017 Q3 | -0.02 USD | 70.02% |
| 2017 Q1 | -0.04 USD | 68.15% |
| 2017 Q4 | -0.07 USD | -346.11% |
| 2017 FY | - USD | 40.0% |
| 2016 Q2 | -0.05 USD | 11.65% |
| 2016 FY | - USD | -19.05% |
| 2016 Q3 | -0.08 USD | -63.89% |
| 2016 Q4 | -0.13 USD | -60.89% |
| 2016 Q1 | -0.06 USD | -607.27% |
| 2015 Q2 | -0.09 USD | -472.85% |
| 2015 Q4 | 0.01 USD | 107.86% |
| 2015 Q3 | -0.14 USD | -61.85% |
| 2015 FY | - USD | 40.0% |
| 2015 Q1 | -0.02 USD | 84.9% |
| 2014 Q2 | -0.10 USD | 9.55% |
| 2014 Q3 | -0.07 USD | 33.47% |
| 2014 FY | - USD | 42.62% |
| 2014 Q1 | -0.11 USD | 45.0% |
| 2014 Q4 | -0.10 USD | -51.06% |
| 2013 Q2 | -0.13 USD | 38.1% |
| 2013 Q4 | -0.20 USD | -100.0% |
| 2013 Q3 | -0.10 USD | 23.08% |
| 2013 Q1 | -0.21 USD | -5.0% |
| 2013 FY | - USD | -10.91% |
| 2012 Q2 | -33.73 USD | -16.83% |
| 2012 Q1 | -28.87 USD | 79.3% |
| 2012 Q4 | -0.20 USD | -33.33% |
| 2012 Q3 | -0.15 USD | 99.56% |
| 2012 FY | - USD | 99.74% |
| 2011 Q2 | -43.81 USD | -2.29% |
| 2011 Q4 | -139.50 USD | -361.77% |
| 2011 Q3 | -30.21 USD | 31.04% |
| 2011 FY | - USD | -69.2% |
| 2011 Q1 | -42.83 USD | 12.13% |
| 2010 Q3 | -40.98 USD | 0.0% |
| 2010 Q4 | -48.74 USD | -18.94% |
| 2010 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -0.60 USD | -198.333% |
| Ampio Pharmaceuticals, Inc. | -10.67 USD | 83.224% |
| Armata Pharmaceuticals, Inc. | -1.91 USD | 6.283% |
| Actinium Pharmaceuticals, Inc. | -1.83 USD | 2.186% |
| Azitra, Inc. | -54.76 USD | 96.731% |
| Chromocell Therapeutics Corporation | -1.28 USD | -39.844% |
| Calidi Biotherapeutics, Inc. | -1.73 USD | -3.468% |
| CEL-SCI Corporation | -0.73 USD | -145.205% |
| iBio, Inc. | -6.50 USD | 72.462% |
| Lineage Cell Therapeutics, Inc. | -0.12 USD | -1391.667% |
| MAIA Biotechnology, Inc. | -1.49 USD | -20.134% |
| Matinas BioPharma Holdings, Inc. | -5.28 USD | 66.098% |
| Navidea Biopharmaceuticals, Inc. | -0.59 USD | -203.39% |
| NovaBay Pharmaceuticals, Inc. | -138.65 USD | 98.709% |
| NanoViricides, Inc. | -0.70 USD | -155.714% |
| Oragenics, Inc. | -9.18 USD | 80.501% |
| BiomX Inc. | -5.10 USD | 64.902% |
| BiomX Inc. | -5.10 USD | 64.902% |
| Protalix BioTherapeutics, Inc. | 0.12 USD | 1591.667% |
| Palatin Technologies, Inc. | -2.02 USD | 11.386% |
| Scorpius Holdings, Inc. | -347.20 USD | 99.484% |